Companies To Watch: KeifeRx ...Middle East

By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein Chris Hoyt Knocking on the door of neuroscience drug approvals.                SNAPSHOT KeifeRx has a full range of neuroscience (NS) drug candidates in development, spanning later-stage clinical assets to several novel, pre-IND technologies. Nilotinib (coded KFRX01) is close to entering a Phase 2b trial for ­­­treating early Alzheimer’s disease; and bosutinib (KFRX02) is ready to enter a Phase 2b trial in Lewy body dementia. Nilotinib is a reformulation of the existing drug branded as Tasigna, a tyrosine kinase inhibitor (TKI) indicated for chronic myeloid leukemia. Keife

Read More Details
Finally We wish PressBee provided you with enough information of ( Companies To Watch: KeifeRx )

Also on site :

• This Common Over-the-Counter Medication May Harm Brain Health, Doctors Say—Do You Take It?
• In Q1 2025, enterprise SaaS M&A deal count hit 210, according to PitchBook
• Downtown Lincolnton on lockdown after 'credible threat,' police say no active shooter